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1. Introduction 
Inhibition of fatty acid synthesis by 3',5'-cAMP or 
its dibutyryl derivative (db cAMP) has been described 
in liver [1-5] ,  but no inhibitory action was detect- 
able in adipose tissue [3,4].  A stimulation of insulin 
release by this nucleotide has been suggested to explain 
this last result. An other explanation could be that 
the hepatic fatty acids synthesis inhibition was only 
apparent and due to a dilution effect caused by 
glycogenolysis induced by this nucleotide [3]. It was 
of interest, herefore, to determine whether 3',5'-cAMP 
acts directly on the liver fatty acid synthesis either by 
repression of the synthesis of the corresponding 
enzymes or by decreasing their activity. To test the 
role of a dilution of the radioactive precursor by 
endogenous glucose, we studied in parallel the db 
cAMP action on fatty acid synthesizing enzymes and 
on glycogen metabolism in presence and absence of 
an inhibitor of the protein synthesis. A decrease of 
the incorporation of various precursors by db cAMP 
into the liver fatty acids does not occur in vitro, and 
the inhibitory effect observed in vivo disappears if the 
animals have been deprived of their hepatic glycogen. 
These facts indicate that 3',5'-cAMP exerts no inhibitory 
action on fatty acid synthesis, as such and that a dilu- 
tion by hepatic glycogenolysis is responsible for the 
appearent decrease of the fatty acid synthesis caused 
by 3',5'-cAMP in vivo. 
2. Experimental 
2.1. General methods 
Liver glycogen and radioactivity were measured 
after extraction of the organ with boiling KOH, pre- 
cipitation with ethanol and transformation i to acetyl- 
glycogen [6]. The acetyl glycogen was dissolved in 
acetic acid and counted in a three-channel Packard 
Tri-Carb liquid scintillation spectrometer (5 g of PPO 
and 300 of POPOP per litre of toluene). 
Fatty acids were extracted from the saponified 
mixture and counted using the same scintillation mix- 
ture. Corrections for quenching were made according 
to Hendler [7]. 
To determine the activities of the fatty acid syn- 
thesis enzymes, portions of liver were homogenized 
in cold 0.25 M sucrose in a Potter-Elvehjem homo- 
genizer with a Teflon pestle. The homogenates were 
centrifuged at 2600 rpm for 15 min at 4 °. The super- 
natants were used for the assay of fatty acid synthetase 
[8] and recentrifuged in a Spinco model L ultracen- 
trifuge at 30,000 rpm for 30 min for the assay of 
acetyl-CoA carboxylase [9]. 
2.2. Treatment of  animals 
Experiment 1: Mice (Swiss strain, 30 g) were 
divided into 3 equal groups: mice of the first group 
received puromycin (6 mg, i.p.) and twelve minutes 
later dibutyryl cAMP (6 mg, i.p.). The mice of the 
second group received only dibutyryl cAMP. 48 min 
later, mice of the three groups were given glucose- 
6-3H intravenously. Twelve minutes after the admini- 
stration of tracer the animals were killed. 
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Experiment 2: The treatment of animals was the 
same as in the previous experiment except that the 
radioactive precursor was L-alanine-3H (G). 
Experiment 3: This experiment is divided in two 
parts: (a) In the first part, the mice received b cAMP 
(6 rag, i.p.) or NaC1 (0.9%) (controls) followed 60 
min later by an intravenous injection of acetate-1 -~4C. 
They were killed 12 min after the administration of  
the radioactive presursor. (b) In the second part, the 
mice received two successive injections of db cAMP 
(4 mg/ml, i.p.) or NaC1 0.9% (controls) at 30 min in- 
tervals. 30 min after the second injection they were 
given acetate-l-14C intravenously and were killed 12 
min later. The data were evaluated statistically by 
means of the Student test. Values for p>0.05 were 
taken to indicate non-significant changes. 
3. Results 
Experiment 2 (see table 2): In vivo, db cAMP sig- 
nificantly inhibits the incorporation of L-alanine-aH 
(G) into liver fatty acids. Puromycin at doses which 
inhibit protein synthesis, does not prevent his in- 
hibition and also has no action upon the controls. 
In vitro, in the same animals, the activities of acetyl- 
CoA carboxylase and fatty acid synthetase are not 
modified after the administration of db cAMP. Puro- 
mycin administered in vivo decreases the liver glycogen 
concentration and does not suppress the lowering 
action of db cAMP on the liver glycogen concentration. 
Experiment 3 (see table 3): The administration of 
two successive injections of bd cAMP shows that under 
these conditions, i.e. when liver glycogen concentra- 
tion is low, this nucleotide does not decrease the in- 
corporation of acetate-l-14C into liver fatty acid in 
vivo. A single injection of  db cAMP, in contrast, de- 
creases the acetate incorporation i to liver fatty acids. 
Experiment I (see table 1): The glycogen con- 
centration is strongly decreased by db cAMP in presence 
or absence of puromycin. The specific radioactivity 
is about 2 fold higher in the db cAMP-treated animals 
than in the controls. The total radioactivity of  glycogen 
is several fold lower in db cAMP-treated animaks than 
in the controls. Puromycin exerts no significant effect 
on the action of  db cAMP. 
4. Discussion 
The present results indicate that db cAMP has no 
direct inhibitory action on the fatty acid synthesis. 
In fact, it does not inhibit the fatty acid synthesis in 
in vitro experiments, i.e. under conditions where con- 
centrations of  substrates and cofactors were optimum 
Table 1 
In vivo effect of db cAMP on the glycogen hepatic oncentration a d synthesis n presence or absence of puromycin. 
Glycogen weight Specific radioactivity Total radioactivity 
(mg/g liver) og glycogen (dpm/mg) of hepatic glycogen 
Controls '¢ < ,¢ 
db cAMP p <0.001 














n.s .  
844 





1,476 p <0.01 
¢ 
n.s .  
1,490 
Puromycin db cAMP Glucose-6-aH Killed 
(6 mg, i.p.) (10 ~Ci, i.v.) 
0 rain 12 rain 60 rain 72 min 
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Table 2 
Action of db cAMP on the liver fatty acids synthesis in vivo and in vitro. 
December 1970 
Total radioactivity Activity of the enzymes of fatty acids synthesis Protein 
of fatty acids syn- (specific Glycogen 
thesized in vivo Acetyl-CoA carboxylase Fatty acids synthetase radioactivity) (mg/g liverL 
Precursors L-Alanine-3H (G) Acetyl'C°A'l'14C Mal°nyl'C°A-I'3J4C L-Alanine-aH (G) 
incorporated incorporated 
Controls < I < 
Controls + 







p < 0.005 
4' 




db cAMP + 
6,720 puromycin 
586,100 < 3,480,000 < 
f f 
p <0.05 n.sr 
4' 4' 
933,400 n.s. 3,700,000 
t f 
p = 0.05 n.s. 
4' 4' 





237.4 < q 27.9 
p <0.001 p <0.05 
4' 4' 
130.6 n.s. 6.6 
t t 
p <0.001 p <0.01  
4' 4' 
235.6 < 1.45 
f f 




Puromycin db cAMP 
(6 mg, i.p.) (6 mg, i.p.) 
4' 4' 
0 min 12 min 
for this process. Hence the two key enzymes of fatty 
acid synthesis, acetyl-CoA carboxylase and fatty acid 
synthetase are not affected by db cAMP. A modifica- 
tion of the concentration of a substrate or a cofactor 
is probably responsible for the inhibition in vivo. This 
inhibition is probably only apparent and due to a dilu- 
tion effect consecutive to glycogenolysis induced by 
this nucleotide. The radioactivity of the applied labeled 
precursor would be diluted by acetyl-CoA through 
glycogen degradation. 
This last assumption is supported by the following 
facts: first, in vivo, the inhibitory effect appears only 
in liver and not in the carcass or in adipose tissue with 
cAMP or its dibutyryl derivative [3] or with cGMP 
[4] ; second, the two successive administrations of db 
cAMP failed to inhibit the liver fatty acid synthesis 
in vivo. Thus when the animals have been deprived of 
glycogen by a first injection of db cAMP, the inhibito- 
ry effect of this compound isappears. It is also inter- 
esting that while it is not possible to provoke a dilution 
effect by exogenous glucose [10], an overload of in- 
traceUular glucose can dilute acetyl-CoA. From these 
L-Alanine-a H (G) Killed 
(10 ~tCi, i.v.) 
60 min 72 min 
results it also appears that not only is glycogenolysis 
stimulated in vivo by 3',5'-cAMP but also the synthesis 
of glycogen is inhibited. Indeed, at the time When the 
synthesis of glycogen from radioactive acetate begins, 
the glycogenolytic action of cAMP is almost finished 
(unpublished results). If glycogen synthesis was un- 
impaired, the specific radioactivity of the remaining 
glycogen would be expected to be much higher than 
we have found. This suggests that both glycogen syn- 
thetase and phosphorylase are modified in vivo as in 
vitro [ 11-13] under the influence of cAMP. This 
nucleotide xerts its action not on the synthesis of 
these enzymes but on their activities, probably by in- 
ducing an immediate allosteric modification as puro- 
mycin does not prevent its action. It is surprising that 
in vivo as in vitro, cAMP exerts an effect similar to 
glucagon or epinephrine on the metabolism of glyco- 
gen [14-17] but does not have the same action on 
the fatty acid synthesis [ 18, 19], unless the decrease 
of fatty acids synthesis provoked by these hormones 
is due to the same phenomenon of dilution. 
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Table 3 
Comparison of the effect of a single and of two successive in- 
jections of db cAMP on the fatty acid synthesis and glycogen- 
olysis in mice liver. 
Total radioactivity of Hepatic glycogen 
fatty acids (mg/g of liver) 
Controls 69,000 36.6 
¢ t 
p < 0.005 p < 0.001 
db cAMP 26,700 1.5 
db cAMP Acetate-l-14C Killed 
(6 mg, i.p.) (2 ~Ci, i.v.) 
0 rain 60 min 72 min 
Total radioactivity of Hepatic glycogen 
fatty acids (mg/g of liver) 
Controls 69,300 41.4 
t t 
n.s. p ' (  0.001 
db cAMP 90,000 2.07 
db cAMP db cAMP Acetate-l-14C Killed 
(4 mg, i.p.) (4 rag, i.p.) (2/~Ci, i.v.) 
0 min 30 min 60 min 72 min 
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